Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Autor: Nicola Polverelli, Michele Cavo, Daria Sollazzo, Lucia Catani, Bruno Martino, Elena Sabattini, Giulia Benevolo, Gioia Colafigli, Giovanni Martinelli, Margherita Perricone, Anna Campana, Nicola Vianelli, Giuliana Alimena, Russel Edward Lewis, Roberto Latagliata, Alessia Tieghi, Francesca Palandri, Maura Nicolosi, Umberto Vitolo, Laura Godio, Massimo Breccia, Mara Riminucci, Francesco Merli
Rok vydání: 2016
Předmět:
Zdroj: American Journal of Hematology. 92:37-41
ISSN: 0361-8609
DOI: 10.1002/ajh.24572
Popis: Although infectious complications represent a relevant cause of morbidity and mortality in patients with myelofibrosis (MF), little is known about their incidence, outcome and risk factors. We retrospectively evaluated a cohort of 507 MF patients, diagnosed between 1980 and 2014 in five Italian hematology centers, to define the epidemiology of infections and describe the impact of ruxolitinib (RUX) treatment. Overall, 112 patients (22%) experienced 160 infectious events (grade 3-4, 45%) for an incidence rate of 3.9% per patient-year. Infections were mainly bacterial (78%) and involving the respiratory tract (52% of cases). Also, viral (11%) and fungal infections (2%) were recorded. Overall, infections were fatal in 9% of the cases. Among baseline features, high/intermediate-2 IPSS category (HR 1.8, 95%CI:1.2-2.7; p=0.02) and spleen length ≥10 cm below left costal margin (HR 1.6, 95%CI:1.1-2.5; p=0.04) were associated with higher infectious risk in multivariate analysis. Overall, the rate of infections was higher in the cohort of 128 RUX-treated patients (44% vs. 20%, p
Databáze: OpenAIRE
Externí odkaz: